Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- (-) Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 39 Results
More Than Just One Number: Assessing The Value of Innovative Treatments
In a commentary for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and CEO Dan Leonard takes a closer look at what changes are needed to ensure that value assessments can…
NPC Weighs in on ICER’s Approaches to Valuing Cures
Within the last few years, we’ve seen the development of treatments to cure specific types of blindness, cancers and hepatitis C. In coming years, we’re anticipating the Food and Drug Administration…
Value Assessments: Incorporating Patient Benefits and Perspectives in ICER Reviews of Allergy and Asthma Treatments
Tonya Winders, CEO and President, Allergy & Asthma Network (AAN), discusses her involvement in the peanut allergy value assessment process and shares her experiences in working with her members…
NPC in AJMC: Why We Need Multiple Measures of Cost-Effectiveness in the US
In an editorial for The American Journal of Managed Care, NPC Chief Science Officer and Executive Vice President Dr. Robert Dubois explores the pitfalls of assigning only one organization the…
NAMI Highlights Concerns With ICER's Review of TRD
Seven percent of adults in the U.S. — an estimated 16 million people — experienced at least one major depressive episode in 2016 alone. Depression can be difficult to treat effectively because of…
Public Input Is a Key Way to Improve Value Assessment Process
This week, the Institute for Clinical and Economic Review (ICER) has announced that it is planning to revise its value assessment framework process. In a perfect world, every framework developer…
In Value Assessment, Additional Voices Bring Much-needed Alternative Perspectives
In an interview published in the Journal of Clinical Pathways, the Innovation and Value Initiative details why value assessment is a critical field in the future of health care, highlights patient…
NPC in in Specialty Pharmacy Times: Aiming for Value Over Volume in Cancer Drug Spending
In his latest column for Specialty Pharmacy Times, NPC President Dan Leonard takes a closer look at a presidential panel's report on "Promoting Value, Affordability, and Innovation in Cancer Drug…
NAMI Weighs in on Value Assessment and ICER Engagement
Andrew Sperling, Director of Legislative Advocacy for the National Alliance on Mental Illness (NAMI), caught up with NPC President Dan Leonard to chat about concerns raised by mental health advocates…
Where Are They Now: Checking In With Former NPC Intern Dan Danielson
Dan Danielson, MS, currently a senior clinical manager at Premera Blue Cross, participated in NPC’s pharmaceutical internship program in 1993. Mr. Danielson chatted with us to answer a few questions…
NPC Chief Science Officer Robert Dubois to Address Value in Personalized Medicine at 13th Annual Personalized Medicine Conference
At the 13th Annual Personalized Medicine Conference, hosted by the Personalized Medicine Coalition, NPC's Dr. Robert W. Dubois will explore why health care stakeholder viewpoints on the value of a…
IVI Introduces Transparent Approach for Value Assessment
The Innovation and Value Initiative (IVI) released its first assessment of treatments for rheumatoid arthritis using its new approach toward value assessment. NPC is still evaluating IVI’s new…
NPC in AJPB: Guiding Practices for Patient-Centered Value Assessment
In response to growing concerns about health care costs, during the past few years, we’ve seen an increase in the development and use of value assessment frameworks. A variety of physician, payer and…
Appropriate Value Assessment Entails A Broad Perspective Of Impact and A Comprehensive Use of Evidence
NPC Chief Science Officer and Executive Vice President Robert W. Dubois looks at recent publications that highlight the need to consider a societal perspective when assessing value and utilize real…
An Important Dialogue About Orphan Drugs
While it’s encouraging to see that the Institute for Clinical and Economic Review (ICER) began the conversation about the value of orphan drugs, treatments that are used for conditions affecting very…
NPC is Going to ISPOR’s 22nd Annual International Meeting – Are You?
NPC will be at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, held May 20-24 in Boston, to lead issue panels and workshops,…
The Evolution of Value Assessment
A Health Affairs Blog post by NPC Chief Science Officer Robert Dubois, MD, PhD, and Vice President for Health Services Research Kimberly Westrich, MA, identified several key considerations that could…
How Is the Multiple Sclerosis Community Engaging on Value Assessment?
NPC President Dan Leonard caught up this week for a Q&A with Lisa Skutnik, President of the MS Coalition, to discuss how the value of multiple sclerosis (MS) treatments is being assessed,…
Engaging With ICER: National Psoriasis Foundation Opens Up on Value Assessment
NPC President Dan Leonard chatted with Leah Howard, Vice President of Government Relations and Advocacy, National Psoriasis Foundation, about value assessment frameworks and how her organization is…